News There's good news for RSV jab firms at delayed ACIP meeting GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.
News GSK makes fresh neuroscience foray with £2bn+ ABL deal Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.
News GSK ends decades-long hiatus in oral antibiotics for UTIs The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.
News GSK taps into UK health data for dementia study GSK joins with two UK research organisations to explore a possible link between its shingles vaccine Shingrix and a reduced risk of dementia.
News GSK bows to Trump pressure and pauses diversity policies GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.
News FDA sets June date for Gilead's twice-yearly HIV PrEP Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.